Recent advances in theranostics and oncology PET: emerging radionuclides and targets

Watabe, Tadashi; Hirata, Kenji; Iima, Mami et al.

Annals of Nuclear Medicine, 2025, 39(9), 909-921

アクセス数:62件（2025-12-05 17:21 集計）

固定URL: https://hdl.handle.net/11094/102738

閲覧可能ファイル 

ファイル フォーマット 利用条件 サイズ 閲覧回数 利用開始日 説明 information
AnnNuclMed_39_9_909 pdf なし 1.26 MB 81 2025.09.19  
Creative Commons : 表示

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

タイトル
Recent advances in theranostics and oncology PET: emerging radionuclides and targets
著者
NRID
1000090648932 1000090648932
ORCID
0000-0001-8658-2395 0000-0001-8658-2395
researchmap permalink
twosaka2018 twosaka2018
Scopus Author ID
57421862900 57421862900
著者名
Watabe, Tadashi
NRID
1000030431365 1000030431365
著者名
Hirata, Kenji
NRID
1000060748797 1000060748797
著者名
Iima, Mami
NRID
1000000546872 1000000546872
ORCID
0000-0002-0911-6769 0000-0002-0911-6769
researchmap permalink
myMY3434 myMY3434
Scopus Author ID
36891136200 36891136200
著者名
Yanagawa, Masahiro
NRID
1000080719485 1000080719485
著者名
Saida, Tsukasa
NRID
1000010838981 1000010838981
著者名
Sakata, Akihiko
NRID
1000090565657 1000090565657
著者名
Ide, Satoru
NRID
1000040957057 1000040957057
著者名
Honda, Maya
NRID
1000070878511 1000070878511
著者名
Kurokawa, Ryo
NRID
1000080463743 1000080463743
著者名
Nishioka, Kentaro
NRID
1000080732685 1000080732685
著者名
Kawamura, Mariko
NRID
1000080813336 1000080813336
著者名
Ito, Rintaro
NRID
1000050535820 1000050535820
著者名
Takumi, Koji
著者名
Oda, Seitaro
著者名
Sugawara, Shunsuke
NRID
1000090622027 1000090622027
著者名
Sofue, Keitaro
NRID
1000090779480 1000090779480
著者名
Ueda, Daiju
NRID
1000050242863 1000050242863
著者名
Naganawa, Shinji
キーワード等
Astatine
Positron emission tomography
PSMA
Radioligand therapy
SSTR
Terbium
Theranostics
内容
The version of record of this article, first published in Annals of Nuclear Medicine 39 (2025), is available online at Publisher’s website: https://doi.org/10.1007/s12149-025-02090-z.
抄録
Theranostics, a novel integrated approach that combines cancer diagnosis and therapy by switching the radionuclide, has attracted growing attention. Various oncology PET probes other than FDG have been developed for the highly sensitive and precise detection of many types of cancer with the advancements in PET scanners, supporting the innovative development in theranostics. In therapeutic applications, radioligand therapy targeting somatostatin receptors (SSTR) and prostate-specific membrane antigen (PSMA) has already demonstrated significant clinical benefits. Terbium-161 (¹⁶¹Tb) has emerged as a new beta and Auger electron emitter, showing greater therapeutic efficacy compared to ¹⁷⁷Lu. Alpha emitters, such as astatine (²¹¹At), are currently being evaluated in investigator-initiated clinical trials, with preliminary efficacy data reported for [²¹¹At]NaAt in patients with radioiodine-refractory thyroid cancer. Novel pan-tumor targeting agents, such as TROP-2, Nectin-4, LAT1, GPC-1, and EphA2, are also under development, and clinical translation of radioligand therapy is anticipated. These innovations in theranostics are expected to further broaden the scope of precision medicine in oncology.
出版者
Springer
収録物名
Annals of Nuclear Medicine
巻(号)
39(9)
ページ
909-921
刊行年月
2025-07-27
言語
英語
ハンドルURL
https://hdl.handle.net/11094/102738
PISSN
09147187
eISSN
18646433
関連情報 (isIdenticalTo)
DOI (出版社版)
https://doi.org/10.1007/s12149-025-02090-z
アクセス権
open access
権利情報
This article is licensed under a Creative Commons Attribution 4.0 International License.
出版タイプ
Version of Record
カテゴリ
学術雑誌論文 Journal Article